Creatio in 2023

At Creatio 2023, we were a skilled and multidisciplinary team comprising 40 individuals, united by the common goal of delivering innovative solutions based on advanced therapies with the goal of increasing the efficiency of the healthcare system and improving quality of life across society.​

In the year 2023, Creatio demonstrated an unwavering commitment to cutting-edge research in advanced therapies. Notably, our excellence in research, preclinical and clinical fields were acknowledged through the successful participation in 10 research projects and closing of 51 agreements with public and private entities. Further reinforcing our capabilities, we consolidate the Preclinical studies area by acquiring the experimental toxicology platform – UTOX – of the PCB. This enables Creatio to offer support along the entire chain of a product development, incorporating toxicology studies essential for regulatory approval and clinical translation. In the Clinical production area, Creatio continued to foster collaborations with hospitals and companies through research contracts and services, ensuring a continuous level of excellence.

On the educational site, Creatio contributed to enrich the scientific community, with 9 students from the research and clinical production areas conducting the PhD, two of which disserted the thesis on 2023.

In summary, 2023 has been a striking year for Creatio, reaffirming our position as a leading academic center in advanced therapies and playing a crucial role in the field.

We express our heartfelt gratitude to the entire team, clients, and collaborators for their unwavering effort, dedication, trust, and support. Their belief in our values and mission has propelled us to achieve significant milestones.

As we embark in 2024, we hope that it will be as good as 2023, filled with continued success and opportunities for further contribution to the advancement of the healthcare system.

Areas of work

Our activity